Floatz logo

(+)-VINCRISTINE

Endocrine Gland Neoplasms

Xiaoxiang ChenSmall moleculePhase 2Dormant
CCC
53/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
38/ 100
Competitive Position
95/ 100

Competitive context

1 Active assets in the Endocrine Gland Neoplasms cohort.

Asset / SponsorPhaseRating
Irinotecan
Xiaoxiang Chen
Phase 2BB
DEXAMETHASONE
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2B
Trabectedin
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Phase 2B
Niraparib
Xiaoxiang Chen
Phase 2CCC
Eloxatin
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Phase 1/2CCC

View all 12 →

Same molecule, other indications

(+)-VINCRISTINE is also rated in:

anaplastic large cell lymphomaDormant
BBB
Indicative ·
78 / 100
View asset →
mycosis fungoidesDormant
BBB
Indicative ·
78 / 100
View asset →
adult acute lymphoblastic leukemiaDormant
BBB
Indicative ·
77 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →